Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: amyotrophic lateral sclerosis gene therapy - Ceregene/Salk Institute

Drug Profile

Research programme: amyotrophic lateral sclerosis gene therapy - Ceregene/Salk Institute

Alternative Names: AAV-IGF-1; ALS gene therapy - Ceregene/Salk Institute; CERE-135; IGF-1 gene therapy

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Salk Institute
  • Developer Ceregene
  • Class Gene therapies
  • Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
  • 01 Oct 2013 Ceregene has been acquired by Sangamo BioSciences
  • 19 Apr 2013 Development of CERE 135 (AAV-IGF1) is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top